Verily Lands ARPA-H Contract to Build AI Data Hub for ICU Moonshot

DALLAS, TX – October 01, 2026 – In a move that underscores the growing convergence of commercial artificial intelligence and high-stakes federal medical research, Verily Health Inc. has been tapped by the Advanced Research Projects Agency for Health (ARPA-H) to serve as the data backbone for a highly ambitious critical care initiative. The precision health company will act as an Acceleration Platform performer for the agency's Critical Illness Immunological Reprogramming and Control Point Learning Engine—better known as the CIRCLE program.

The mandate is as clear as it is daunting: build and operate the centralized database and research environment that will allow scientists to analyze patient immune responses in real time. Backed by up to $144.9 million in total program funding spread across multiple performers over five years, CIRCLE aims to equip intensive care clinicians with the predictive tools necessary to halt organ damage before it becomes irreversible. The ultimate objective is a 25 percent reduction in average ICU lengths of stay nationwide.

For a healthcare system buckling under the financial and operational weight of critical care, achieving this goal would represent a paradigm shift. Yet, the selection of the Alphabet-associated entity for this foundational role tells a broader story about the evolution of health technology. It signals a definitive pivot away from consumer-facing gadgets toward the unglamorous, highly lucrative world of enterprise data infrastructure—the plumbing of the modern medical economy.

The 25 Percent Moonshot: Cracking the Critical Care Code

To understand the magnitude of the CIRCLE program, one must first understand the chaotic reality of the intensive care unit. Critical illness, particularly conditions like sepsis, triggers a complex and rapidly evolving immune response. A patient's immune system can swing violently from a hyperactive state—attacking the body's own tissues—to a suppressed state that leaves them vulnerable to secondary infections.

Currently, intensive care is largely reactive. Clinicians rely on traditional laboratory tests that are often too slow to capture these dynamic immunological shifts, forcing them to treat the resulting organ damage rather than the underlying immune dysfunction. Despite decades of research and advances in supportive care, there are still no FDA-approved therapies that directly target and correct the immune system failures responsible for most forms of critical illness. Many who survive the initial trauma are left battling post-ICU syndrome for months or years.

ARPA-H, an agency modeled after the defense sector's DARPA and designed to fund high-risk, high-reward medical breakthroughs, is attempting to rewrite this narrative. The CIRCLE program is built on a "measure-model-modulate" framework. It seeks to integrate rapid biomarker measurement with precision immune modulation, moving the needle from reactive triage to proactive intervention.

Central to this effort is the creation of AI-powered "digital twins" of patients' immune systems. By simulating the patient's biological state, researchers hope to model various intervention strategies and interrupt the cascade toward organ failure. As CIRCLE Program Manager Yoram Vodovotz has noted, the initiative seeks to unlock the ability to track and modulate the body's immune response like never before, giving medical professionals the proactive tools they have long lacked.

Breaking Down the Data Silos in Sepsis

However, artificial intelligence and digital twin models are only as effective as the data that feeds them. This is where the technical bottleneck has historically choked clinical innovation, and it is precisely the bottleneck the newly appointed Acceleration Platform performer is tasked with clearing.

Health data is notoriously fragmented, locked away in proprietary electronic health record systems, incompatible formats, and institutional silos. To build a functional digital twin of an immune system, researchers need access to vast amounts of multimodal data—ranging from genomic profiles and continuous vital signs to experimental biomarker readings. Historically, harmonizing this data required armies of bioinformaticians spending months cleaning datasets before a single algorithm could be trained.

Under the terms of the agreement, the company will deploy its flagship data platform, Verily Pre, and its Verily Workbench environment to serve as CIRCLE's secure collaborative research hub. The platform is responsible for ingesting, harmonizing, and standardizing public and private critical illness datasets in real time, alongside the novel data generated by the program's other research teams. These teams include prominent academic medical centers like the University of Vermont and the Icahn School of Medicine at Mount Sinai, which are focused on developing dynamic immune descriptors and digital twin generators.

Crucially, the platform will not just be a static repository. The technology firm is tasked with developing AI-driven discovery and search tools that will allow clinical researchers to navigate the data lake intuitively. By eliminating the need for researchers to write raw, complex database queries, the platform aims to democratize data access. It allows scientists to focus on identifying immunological patterns rather than wrestling with data architecture. Overcoming the interoperability, security, and privacy hurdles inherent in multi-institution data sharing will be the true test of the platform's viability, setting a precedent for future federal health IT contracts.

Big Tech's Health Spin-Offs Bet on Federal Infrastructure

Beyond the clinical implications, this contract illuminates a significant strategic repositioning within the health tech sector. Verily, originally born as Google Life Sciences, has spent the last several years refining its identity. While early iterations of the company explored everything from glucose-sensing contact lenses to consumer wearables, the current leadership has steered the ship toward a more foundational, enterprise-focused horizon. They are betting that the real value in health tech lies in B2B infrastructure.

Securing a central role in an ARPA-H flagship program validates this commercial pivot. It demonstrates that the company's investments in high-security, compliant data architecture are paying off in the highly competitive federal marketplace.

"We're honored that ARPA-H selected Verily Health to build this program's data foundation. It reflects the trust federal researchers are placing in Verily Pre as a platform for complex, multi-institution science, and it's exactly the kind of opportunity that accelerates our vision to build a trusted foundation for healthcare," said Stephen Gillett, Chairman and CEO of Verily Health.

This public-private partnership model highlights a growing reliance by federal health agencies on commercial AI platforms to solve complex, national-scale healthcare challenges. Building the infrastructure required for real-time, multi-modal data analysis from scratch would take the government years and billions of dollars. By leveraging existing commercial platforms, ARPA-H can theoretically accelerate its timeline from decades to years.

For the tech industry, these federal contracts serve as a vital commercialization bridge. They provide not only significant funding but also an unparalleled testing ground for precision health platforms. If the Verily Pre platform can successfully manage the immense complexity of real-time ICU immune data across multiple academic institutions, it will emerge as a battle-tested standard for the broader healthcare enterprise market.

As the 2026 landscape continues to be defined by the integration of artificial intelligence into critical infrastructure, the CIRCLE program stands as a prime example of how strategic innovation is being deployed. The success of this endeavor will not be measured merely in algorithms trained or datasets harmonized, but in the tangible reduction of suffering in the nation's intensive care units.